-
News
In 2022, EMA recommended 89 medicines for marketing authorisation
In 2022, EMA recommended 89 medicines for marketing authorisation. Of these, 41 had a new active ingredient…
Leggi » -
Editorial notes
After the purchase of Sofar, Alfasigma fires 333 workers, 221 of whom are informants
Alfasigma in August 2022 announced that it had reached an agreement for the acquisition of the entire share capital of Sofar Spa. Alfasigma declared that with…
Leggi » -
News
R&D spending doesn't justify high drug prices. An analysis on the BMJ
The "British medical journal" published an interesting analysis entitled "High drug prices are not ...
Leggi » -
News
Too many VAT numbers in Italy compared to European Partners
Italy is the country of the VAT numbers Blue Suitcase – 15 February 2023 by Mattia Marasti The labor market in…
Leggi » -
News
FRANCE. Roche and Novartis acquitted, they will not have to pay 444 million euros
The maxi-fines dating back to last 2020 and imposed in France on the two pharmaceutical giants for abuse of position have been canceled…
Leggi » -
First floor
A Whistleblower at Filctem Congress: "We must take a path that is compliant with the law"
For the first time, at least we have no memory of similar cases, a Scientific Representative, Antonio Daniele, presented a report…
Leggi » -
News
AIFA updates the Transparency Lists
AIFA press release. February 15, 2023 In order to allow the Regions and autonomous Provinces to uniformly apply what…
Leggi » -
News
Ethics Committees. Clinical trials of medicines and medical devices, the decrees on ethics committees in the Journal
"With the signing of the four decrees on Ethics Committees, a decisive step has been taken, which has been awaited for years, towards…
Leggi » -
News
SNAMI declares a state of agitation to protect increasingly harassed doctors!
SNAMI dichiara lo stato di agitazione a tutela dei medici sempre più vessati ! Roma, 13 febbraio 2023 – Il…
Leggi » -
News
Deloitte reports. In 2022, the rate of return on investment has decreased. The top 20 companies spent 139 billion on R&D
"Measuring the return from pharmaceutical innovation 2022", the thirteenth annual report of the Deloitte Center for Health, has been published. The…
Leggi »